WaveMan
WaveMan · Company
PLSH · Panacea Life Sciences Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PLSH Panacea Life Sciences (PLSH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001552189
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Panacea Life Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PANACEA LIFE SCIENCES HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Buttorff Leslie
CEO
BUY
2023-09-20 SECtraded 2023-09-18
20,000
$4.8K
-60.1%
Context
  • 67 earlier Form 4 trades (code P or S) here by this insider (67 buys), the last on Jun 9, 2023.
  • -12.0% median (-3.6% mean) 90-day return after 30 previous buys.
  • The trade is 1.3% of the 1,533,949 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO Buttorff Leslie bought about $4.8K of PLSH on Sep 18, 2023.
Buttorff Leslie
CEO
BUY
2023-06-12 SECtraded 2023-06-09
3,000
$1.3K
-83.9%
Context
  • 66 earlier Form 4 trades (code P or S) here by this insider (66 buys), the last on May 23, 2023.
  • -12.0% median (-4.0% mean) 90-day return after 30 previous buys.
  • The trade is 0.2% of the 1,513,949 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO Buttorff Leslie bought about $1.3K of PLSH on Jun 9, 2023.
Buttorff Leslie
CEO
BUY
2023-05-23 SEC
500
$250
-82.3%
Context
  • 65 earlier Form 4 trades (code P or S) here by this insider (65 buys), the last on May 19, 2023.
  • -12.0% median (-4.4% mean) 90-day return after 30 previous buys.
  • The trade is 0.1% of the 751,449 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO Buttorff Leslie bought about $250 of PLSH on May 23, 2023.
Buttorff Leslie
CEO
BUY
2023-05-23 SECtraded 2023-05-19
4,500
$2.3K
-82.3%
Context
  • 63 earlier Form 4 trades (code P or S) here by this insider (63 buys), the last on May 9, 2023.
  • -12.0% median (-5.1% mean) 90-day return after 30 previous buys.
  • The trade is 0.6% of the 746,449 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO Buttorff Leslie bought about $2.3K of PLSH on May 19, 2023.
Buttorff Leslie
CEO
BUY
2023-05-23 SECtraded 2023-05-19
1,500
$780
-82.3%
Context
  • 63 earlier Form 4 trades (code P or S) here by this insider (63 buys), the last on May 9, 2023.
  • -12.0% median (-5.1% mean) 90-day return after 30 previous buys.
  • The trade is 0.2% of the 750,949 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO Buttorff Leslie bought about $780 of PLSH on May 19, 2023.
70 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 65 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+46.6% year over year
more than 75% of Pharma & Biotech
Margin
-336.1% net margin
below 73% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PLSH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+14.0%12M
-64%-10%+45%+100%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PLSH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in PLSH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PLSH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PLSH financials

Revenue growth
+46.6%
XBRL, annual
Net margin
-336.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.8M
four quarters, 2023-04-01 to 2024-03-31
Net margin, TTM
-277.5%
net income over revenue, 2023-04-01 to 2024-03-31
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-4.67x
TTM operating cash flow over LongTermDebt as filed 2020-12-31 (39 months older than the period end) (includes the current portion)
Return on equity
n/a
average equity is zero or negative
Return on assets
-42.6%
TTM net income over average of 2023-03-31 and 2024-03-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.6M
market value at close 2026-10-26 on 2024-05-01 shares, plus LongTermDebt as filed 2020-12-31 (39 months older than the period end) (includes the current portion), minus cash 2024-03-31
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2023-122022-122021-122020-12
Revenue$2.4M$2.3M$2.1M$9.0M
Gross profit$1.1M$396.5K$540.6K$2.0M
Operating income-$5.5M-$5.7M-$5.9M-$5.3M
Net income-$8.0M-$9.1M-$4.8M-$5.2M
EPS (diluted)-0.48-0.62n/an/a
Operating cash flow-$1.5M-$2.4M-$3.9M-$7.6M
Cash$100.9K$7.0K$19.8K$84.4K
Long-term debtn/an/an/a$335.5K
SEC XBRL, fiscal years, as known on 2026-10-28

PLSH Stock Sonar score 2/7 axes

Find similar shapesCompare
Financial health
31
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-4.67x · 31 pct, sector of 371
Growth
75
Inputs
  • Revenue growth, YoY+46.6% · 75 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
5 not measured: Profitability, Insider conviction, Institutional and government, Risk and compliance, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies